Overview

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Status:
Active, not recruiting

Trial end date:
2026-04-01

Target enrollment:

Participant gender:

Summary

Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.

Phase:

Phase 2

Details

Lead Sponsor:

University of Louisville

Treatments:

Nivolumab